Curevac (CVAC) is a clinical-stage pharmaceutical company. George Tsilis discusses CVAC as it uses a proprietary RNA technology platform. He notes that CVAC is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs. He compares CVAC to JNJ, PFE, MRNA, and NVAX. He goes over how CVAC is up over 20% following it's Covid-19 and flu vaccine advancing to the next stage of testing. Finally, he goes over how CVAC announced a new CEO will step in April 1, 2023. Tune in to find out more about the stock market today.
10 Jan 2023
Morning Trade Live
10 May 2023
Morning Trade Live
09 Mar 2023
Next Gen Investing
18 Apr 2023
The Watch List
14 Mar 2023
Market On Close
03 May 2023
Market On Close
23 May 2023